Clinical Trials
11 trialsNCT03547700 2026-05-06
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT01938833 2025-05-16
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Thomas Jefferson University
Phase 1/2 Terminated
NCT01755975 2024-11-07
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01998035 2024-08-22
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
Phase 1/2 Terminated
NCT02232516 2024-04-10
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
Northwestern University
Phase 2 Unknown
NCT02341014 2024-04-04
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03534180 2023-10-19
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
City of Hope Medical Center
Phase 2 Completed
NCT01302808 2021-01-20
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 1 Completed
NCT01822886 2019-10-14
FIL_GEMRO
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
NCT01738594 2019-08-29
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Northwestern University
Phase 1 Terminated
NCT01979276 2018-06-06
Romi Poma
Weill Medical College of Cornell University
Phase 1/2 Terminated